Pharming Group NV is a biotechnology business based in the US. Pharming Group shares (PHAR) are listed on the NASDAQ and all prices are listed in US Dollars. Pharming Group employs 277 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Pharming Group
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – PHAR – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Pharming Group stock price (NASDAQ: PHAR)Use our graph to track the performance of PHAR stocks over time.
Pharming Group shares at a glance
|Latest market close||$7.86|
|52-week range||$6.10 - $11.60|
|50-day moving average||$7.96|
|200-day moving average||$8.71|
|Wall St. target price||N/A|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$0.16|
Buy Pharming Group shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Pharming Group stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Pharming Group price performance over time
|1 week (2022-06-24)||2.68%|
|1 month (2022-06-03)||-1.92%|
|3 months (2022-04-01)||-9.66%|
|6 months (2022-01-03)||-11.29%|
|1 year (2021-06-29)||N/A|
|2 years (2020-06-29)||N/A|
|3 years (2019-06-29)||N/A|
|5 years (2017-06-29)||N/A|
Is Pharming Group stock undervalued or overvalued?
Valuing Pharming Group stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Pharming Group's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Pharming Group's P/E ratio
Pharming Group's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 49x. In other words, Pharming Group shares trade at around 49x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
However, Pharming Group's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.
Pharming Group's EBITDA
Pharming Group's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $26.9 million.
The EBITDA is a measure of a Pharming Group's overall financial performance and is widely used to measure a its profitability.
To put Pharming Group's EBITDA into context you can compare it against that of similar companies.
Pharming Group financials
|Revenue TTM||$201.9 million|
|Operating margin TTM||10.17%|
|Gross profit TTM||$177.7 million|
|Return on assets TTM||3.29%|
|Return on equity TTM||5.91%|
|Market capitalisation||$509.9 million|
TTM: trailing 12 months
Pharming Group share dividends
We're not expecting Pharming Group to pay a dividend over the next 12 months.
Pharming Group share price volatility
Over the last 12 months, Pharming Group's shares have ranged in value from as little as $6.1 up to $11.603. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Pharming Group's is 1.5501. This would suggest that Pharming Group's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
To put Pharming Group's beta into context you can compare it against those of similar companies.
- Alexion Pharmaceuticals (ALXN.US): 1.2595
- Repligen Corporation (RGEN.US): 0.9769
- Teva Pharma Industries Ltd ADR (TEVA.US): 1.1788
Pharming Group overview
Pharming Group N. V. , a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.
Frequently asked questionsWhat percentage of Pharming Group is owned by institutions?
Currently 0.035% of Pharming Group shares are held by institutions. How many people work for Pharming Group?
Latest data suggests 277 work at Pharming Group. When does the fiscal year end for Pharming Group?
Pharming Group's fiscal year ends in December. Where is Pharming Group based?
Pharming Group's address is: Darwinweg 24, Leiden, Netherlands, 2333 CR What is Pharming Group's ISIN number?
Pharming Group's international securities identification number is: US71716E1055
More guides on Finder
How to buy Intchains Group (ICG) stock when it goes public
Everything we know about the Intchains Group IPO, plus information on how to buy in.
How to buy Biostage (BSTG) stock when it goes public
Everything we know about the Biostage IPO, plus information on how to buy in.
How to buy Wang & Lee Group (WLGS) stock when it goes public
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
How to buy OptMed (OMED) stock when it goes public
Everything we know about the OptMed IPO, plus information on how to buy in.
How to buy Lichen China (LICN) stock when it goes public
Everything we know about the Lichen China IPO, plus information on how to buy in.
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
How to buy Warrantee (WRNT) stock when it goes public
Everything we know about the Warrantee IPO, plus information on how to buy in.
How to buy Treasure Global (TGL) stock when it goes public
Everything we know about the Treasure Global IPO, plus information on how to buy in.
How to buy BIOLIFE4D (SAVU) stock when it goes public
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
Ask an Expert